Who Paid My Doc
Garey Noritz
Neurodevelopmental Disabilities Columbus, OH Medical Doctor
NPI 1376572107 CMS profile 198771
700 Childrens Dr, Columbus, OH 43205
General payments
$3,061
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Garey Noritz of Columbus, OH is reported in the CMS Open Payments database as having received $3,061 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 77th percentile of Neurodevelopmental Disabilities profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $1 | 1 | |
| 2021 | General | $2,310 | 1 | |
| 2020 | General | $750 | 1 |
Beside peers
- Garey Noritz
- Neurodevelopmental Disabilities median
- Middle half of Neurodevelopmental Disabilities
- National median
In program year 2025, general payments to Garey Noritz were reported at $0. Among 64 Neurodevelopmental Disabilities profiles paid that year, the median was $136 and the middle half received between $67 and $819.
Show as a table
| Year | Garey Noritz | Neurodevelopmental Disabilities median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $138 | $34–$757 | $163 |
| 2020 | $750 | $63 | $23–$471 | $114 |
| 2021 | $2,310 | $158 | $43–$1,017 | $132 |
| 2022 | $1 | $225 | $76–$1,106 | $149 |
| 2023 | $0 | $228 | $73–$994 | $160 |
| 2024 | $0 | $167 | $57–$1,310 | $164 |
| 2025 | $0 | $136 | $67–$819 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 43 drugsPart D claims
767
Drug cost
$58,929
Branded share of claims
23.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Zyprexa Zydis Olanzapine | Brand | 12 | $15,072 | |
| Linzess Linaclotide | Brand | 24 | $12,714 | |
| Enalapril Maleate | Generic | 13 | $6,267 | |
| Advair Hfa Fluticasone Propion/Salmeterol | Brand | 12 | $3,738 | |
| Fluticasone Propionate Hfa Fluticasone Propionate | Brand | 14 | $3,656 | |
| Lansoprazole | Generic | 11 | $2,527 | |
| Famotidine | Generic | 26 | $1,889 | |
| Alendronate Sodium | Generic | 14 | $1,527 | |
| Methenamine Hippurate | Generic | 13 | $1,249 | |
| Gabapentin | Generic | 44 | $1,220 |
The 10 drugs with the highest cost, of 43 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurodevelopmental Disabilities in Ohio
Maria Cristina Victorio
Neurodevelopmental Disabilities · Akron, OH
Irene Dietz
Neurodevelopmental Disabilities · Cleveland, OH
Laurie Glader
Neurodevelopmental Disabilities · Columbus, OH
Marina Khrizman
Neurodevelopmental Disabilities · Columbus, OH
Lisa Maria Torres
Neurodevelopmental Disabilities · Cleveland, OH
Derek Fletcher
Neurodevelopmental Disabilities · Columbus, OH
Related records
Neurodevelopmental Disabilities in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Neurodevelopmental Disabilities
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.